My research focuses on finding novel immunosuppressive pathways in the tumor microenvironment. My previous research has shown that the signaling through adrenergic receptors impair adaptive and innate immune cells’ function and promote immunosuppression. I am currently investigating the role of neurotransmitters in the tumor microenvironment and trying to uncover novel immunosuppressive pathways that can be targeted by repurposing drugs.
Dr.. Çobanoğlu is PI on an MRF Breakthrough Consortium-Bristol Myers Squibb Young Investigator Research Team Award to Advance the Field of Translational Immuno-Oncology.
My goal is to understand the long-term effect of immune checkpoint blockade therapy. Anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) treatment induces a low response rate (~11%), while anti-programmed cell death-1 (anti-PD-1) treatment mediates a relatively higher response rate (~30%) in patients with melanoma. Both anti-CTLA-4 and anti-PD-1 induce durable responses and mediate a 22% 10-year and 34% 5-year survival rate respectively. However, in order to achieve the durable response, continuous treatment of anti-PD-1 has to be administered while anti-CTLA-4 treatment can only be administered for a short period of time. In addition, 25% of patients who initially respond to these treatment relapse within 2 years. Therefore, it is important to understand the differential effect of checkpoint blockade treatments on the formation of immunological memory.
Dongrui Wang received his PhD from City of Hope Medical Center in California, where he developed chimeric antigen receptor (CAR) T cell therapies targeting brain tumors. His research will focus on understanding the changes that occur in immune cells in response to immune checkpoint blockade therapy including anti-CTLA4 and anti-PD1. As immune checkpoint blockade has resulted in mixed outcomes in patients, it is critical to identify key components of immune cells that mediate the antitumor responses and respond to the therapy. The study also aims to develop combinational approach to further enhance the efficacy of immune checkpoint blockade.
CPRIT Graduate Scholar, John J Kopchik Fellow
Fullbright Research Scholar (France): 2019-2020
Alex Cogdill's publications
Current: Director of Business Development and Strategy, Immunai
Current: Sr. Scientist, Spotlight Therapeutics, Hayward, CA
Sr. Research Assistant
Current: PhD student at UCSD